Scarica l'app Stockscreener
167.31
6.00%
9.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$157.58
Aprire:
$161.76
Volume 24 ore:
1.47M
Relative Volume:
0.57
Capitalizzazione di mercato:
$22.18B
Reddito:
$1.08B
Utile/perdita netta:
$-433.19M
Rapporto P/E:
-49.20
EPS:
-3.4004
Flusso di cassa netto:
$-225.09M
1 W Prestazione:
+3.11%
1M Prestazione:
+2.52%
6M Prestazione:
+64.00%
1 anno Prestazione:
+231.47%
Intervallo 1D:
$160.00
$168.25
Intervallo di 1 settimana:
$155.05
$168.25
Portata 52W:
$51.44
$176.58
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, NTRA, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
167.26 | 19.29B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
587.20 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.73 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
588.06 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
317.92 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
145.10 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Reiterato | Canaccord Genuity | Buy |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Patrick Dempsey Urges Screening With Guardant's Shield Blood Test - Stock Titan
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer - New Castle News
Freenome secures FDA nod for blood-based colorectal cancer test - MedTech Dive
FDA approves Freenome’s blood test for colorectal cancer screening - WTVB
FDA approves Freenome's blood test for colorectal cancer screening - Reuters
Orbimed Advisors LLC Buys Shares of 435,200 Guardant Health, Inc. $GH - MarketBeat
Styrax Capital LP Purchases 18,411 Shares of Guardant Health, Inc. $GH - MarketBeat
First Light Asset Management LLC Sells 14,452 Shares of Guardant Health, Inc. $GH - MarketBeat
Caxton Associates LLP Invests $831,000 in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) stock price, news, quote and history - Yahoo Finance UK
Guardant Health, Inc. $GH Shares Sold by Aristotle Atlantic Partners LLC - MarketBeat
Guardant Health Inc (GH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Guardant Health, Inc. (GH) Stock Forecasts - Yahoo Finance
Guardant Health: An Expensive Price For A Great Company - Seeking Alpha
Guardant Health, Inc. $GH Shares Sold by Atika Capital Management LLC - MarketBeat
Guardant Health Inc (GH) Institutional Confidence - TradingKey
ETFs Investing in Guardant Health, Inc. Stocks - TradingView
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Hsbc Holdings PLC Has $9.13 Million Stake in Guardant Health, Inc. $GH - MarketBeat
Principal Financial Group Inc. Has $17.07 Million Stock Position in Guardant Health, Inc. $GH - MarketBeat
GH|Guardant Health Inc|Price:147.330|Chg%:-2.870 - TradingKey
Guardant Health (GH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Form 4 Guardant Health Inc For: 22 July By Investing.com - Investing.com South Africa
Temasek Holdings Private Ltd Sells 58,526 Shares of Guardant Health, Inc. $GH - MarketBeat
Jennison Associates LLC Sells 966,559 Shares of Guardant Health, Inc. $GH - MarketBeat
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Biomarker Collaboration and Licensing Deals Report 2016-2026Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More - Yahoo Finance
Strong Results Boosted Guardant Health (GH) in Q2 - Yahoo Finance
Guardant Health, Inc. $GH Stock Position Raised by WCM Investment Management LLC - MarketBeat
Amova Asset Management Americas Inc. Sells 156,738 Shares of Guardant Health, Inc. $GH - MarketBeat
EBITDA per share of Guardant Health, Inc. – LSX:A2N5RY - TradingView
Guardant Health Surges 53% on UnitedHealth Coverage Deal — "Single-Drop Blood Test for Cancer" Becomes Reality - finance.biggo.com
Guardant Health Falls as Recent Rally Appears to Cool - Quiver Quantitative
Lobbying Update: $180,000 of GUARDANT HEALTH lobbying was just disclosed - Quiver Quantitative
Guardant Health, Inc. (GH) Stock Analysis: Unpacking a 48% Revenue Growth in the Diagnostics Sector - DirectorsTalk Interviews
Guardant Health, Inc. $GH Stock Position Raised by D.A. Davidson & CO. - MarketBeat
Allspring Global Investments Holdings LLC Lowers Position in Guardant Health, Inc. $GH - MarketBeat
Responsive Playbooks and the GH Inflection - Stock Traders Daily
Future Fund LLC Increases Position in Guardant Health, Inc. $GH - MarketBeat
Fifth Third Bancorp Raises Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Form 144 Guardant Health For: 16 July By Investing.com - Investing.com Nigeria
Guardant Health director Tariq Musa sells $18,941 in stock By Investing.com - Investing.com Nigeria
Form 4 Guardant Health Inc For: 16 July By Investing.com - Investing.com Nigeria
GH Maintains Rating by Guggenheim -- Price Target Raised to $190 - GuruFocus
Guardant Health director Tariq Musa sells $18,941 in stock - Investing.com
Musa Tariq plans sale of Guardant Health (NASDAQ: GH) common stock - Stock Titan
Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It’s Entering the U.S. (TSXV: SEGN) - Benzinga
Guggenheim raises Guardant Health stock price target on Shield data - Investing.com
Guggenheim raises Guardant Health stock price target on Shield data By Investing.com - Investing.com Canada
Goldman Sachs Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $185 - Moomoo
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Guardant Health Inc Azioni (GH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| CLARK IAN T | Director |
Aug 04 '26 |
Sale |
158.92 |
14,180 |
2,253,451 |
2,975 |
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):